Evidence map›Paper›PMID 30238574›Full record

ArticleEuropean journal of heart failure2018

Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.

Wilfried Mullens, Frederik H Verbrugge, Petra Nijst, Pieter Martens, Katrien Tartaglia, Evi Theunissen, Liesbeth Bruckers, Walter Droogne, Pierre Troisfontaines, Kevin Damman and 5 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in European journal of heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06535529 (Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients), which is not on this map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06535529 phase3recruitingstarted 2024, after this paper: background citation

Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients

Ran2024Enrolled60Registered outcomes8Posted comparisons0ConditionsAcute Decompensated Heart FailureArmsAcetazolamide, Dapagliflozin 10mg
PMID 38569758PMID 36027559PMID 37207453PMID 37213994PMID 37415505PMID 38202295PMID 38416359other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022
    Pooled it
  2. The value of urinary sodium assessment in acute heart failure.European heart journal. Acute cardiovascular care · 2021
    Pooled it
  3. Highlights in heart failure.ESC heart failure · 2019
    Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Review
  18. Article
  19. Inpatient Diuretic Management of Acute Heart Failure: A Practical Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 6 countries.

Wilfried MullensZiekenhuis Oost-Limburg, Genk, Belgium.
Frederik H VerbruggeZiekenhuis Oost-Limburg, Genk, Belgium.
Petra NijstZiekenhuis Oost-Limburg, Genk, Belgium.
Pieter MartensZiekenhuis Oost-Limburg, Genk, Belgium.
Katrien TartagliaZiekenhuis Oost-Limburg, Genk, Belgium.
Evi TheunissenZiekenhuis Oost-Limburg, Genk, Belgium.
Liesbeth BruckersHasselt University, Diepenbeek/Hasselt, Belgium.
Walter DroogneUniversity Hospitals Leuven, Leuven, Belgium.
Pierre TroisfontainesCHR Citadelle Hospital, Liege, Belgium.
Kevin DammanUniversity Medical Center Groningen, Groningen, The Netherlands.
Johan LassusHelsinki University Central Hospital, Helsinki, Finland.
Alexandre MebazaaUniversity of Paris Diderot, Paris, France.
Gerasimos FilippatosNational and Kapodistrian University of Athens, Athens, Greece.
Frank RuschitzkaUniversitätsSpital Zürich, Zürich, Switzerland.
Matthias DupontZiekenhuis Oost-Limburg, Genk, Belgium.
Ziekenhuis Oost-Limburg · BECentre hospitalier régional de la Citadelle · BEDélégation Paris 7 · FRHasselt University · BEHelsinki University Hospital · FIKU Leuven · BENational and Kapodistrian University of Athens · GRUniversity Medical Center Groningen · NLUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDecisive evidence on the optimal diuretic agent, dosing schedule, and administration route is lacking in acute heart failure (AHF) with congestion. The Acetazolamide in Decompensated heart failure with Volume OveRload (ADVOR) trial is designed to test the hypothesis that the carbonic anhydrase inhibitor acetazolamide, a potent inhibitor of proximal tubular sodium reabsorption, improves decongestion when combined with loop diuretic therapy in AHF, potentially leading to better clinical outcomes.

methodsThe ADVOR trial is set up as a multicentre, randomized, double-blind, placebo-controlled study, aiming to recruit 519 patients with AHF and clinically evident volume overload. All study participants receive high-dose intravenous loop diuretics as background therapy and are randomized towards intravenous acetazolamide at a dose of 500 mg once daily vs. placebo, stratified according to including study centre and ejection fraction (< 40% vs. ≥ 40%). The primary endpoint is successful decongestion with no more than trace oedema assessed on the third morning after hospital admission, with good diuretic efficacy defined as a urine output > 3.5 L during the first 30-48 h of decongestive treatment. Secondary endpoints include all-cause mortality or heart failure readmission after 3 months, length of hospital stay for the index admission, and longitudinal changes in the EuroQol-5 dimensions questionnaire.

conclusionADVOR will investigate if acetazolamide combined with loop diuretic therapy improves decongestion in AHF with volume overload.

Indexed as

AcetazolamideDiureticsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHeart FailureHumansInjections, IntravenousLength of StayMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicStroke VolumeTreatment OutcomeWater-Electrolyte ImbalanceAcetazolamideDiureticsAcetazolamideCongestionDiureticHeart failure

Identifiers

PMID30238574
OpenAlexW2890636056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.